EARLY RESPONSE TO GLEPAGLUTIDE, A NOVEL LONG-ACTING GLP-2 ANALOG, IN SHORT BOWEL SYNDROME PATIENTS WITH INTESTINAL FAILURE: RESULTS OF 24-WEEK PHASE 3 TRIAL

Tim Vanuytsel  ¹     Ulrich-Frank Pape  ²     Sukanya Subramanian  ³     Francisca Joly  ⁴     Geert J.A. Wanten  ⁵     Georg Lamprecht  ⁶     Marek Kunecki  ⁷     Faqooq Rahman  ⁸     Thor Schutt Svane Nielsen  ⁹     Lykke Bjerglund Graff  ⁹     Mark Berner-Hansen  ⁹     David F Mercer  ¹⁰     Palle Bekker Jeppesen  ^11    
1 University Hospital, Leuven, Belgium
² Asklepios Medical School, Berlin, Germany
³ MedStar Georgetown, Washington DC, United States
⁴ Hospital Beaujon, Clichy, France
⁵ Radboud University Nijmegen Medical Centre (Radboud UMCN), Nijmegen, Netherlands
⁶ University Medical Center Rostock, Rostock, Germany
⁷ M. Pirogow Hospital, Wolczanska, Poland
⁸ University College London Hospitals (UCLH), London, United Kingdom
⁹ Zealand Pharma A/S, Copenhagen, Denmark
¹⁰ Nebraska Medical Center, Nebraska, United States
¹¹ Rigshospitalet, Copenhagen, Denmark

Topic
Hepatobiliary, IBD, Small Intestine & Nutrition

Session
Big steps for coeliac and short bowel

Conference
UEG Week 2023

Citation
United European Gastroenterology Journal 2023; 11 (Supplement 8)